You are here

New Robotic Aid for Drugfree Depression Treatment

Non-Invasive Therapy for Patients Who are Nonresponsive to Antidepressants

MagVenture has added the new FDA-approved robotic platform to its clinical system. The TMS-Cobot, will help further elevate the rapidly growing field of neuromodulation, commonly known as Transcranial Magnetic Stimulation (TMS).

Transcranial Magnetic Stimulation (TMS) therapy–– is an effective, non-invasive option for the large number of patients who fail to respond to antidepressants. During treatment, magnetic pulses are applied with a magnetic coil to a certain part of the patient’s brain. This area is the entry-point for treatment as the pulses reach the neural network that controls mood and emotion, potentially alleviating the depression. Patients are fully awake during treatment and can return to their normal activities immediately following the TMS session. Typically, patients will receive a total of 20–30 sessions, one per weekday.

The new robotic TMS-Cobot provides continuous tracking of the patient’s possible head movements during treatment. It also reduces the manual coil-handling time for TMS operators, which is a key factor for clinics that treat many patients.

TMS-Cobot is FDA-indicated for the spatial positioning and orientation of MagVenture’s TMS Therapy system treatment coil.

Source: MagVenture, February 20, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs